BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The company will send its new findings to the FDA.

Pfizer says its COVID-19 vaccine is 100% effective in younger teens

Pfizer Inc. and German partner BioNTech SE said Wednesday that a Phase 3 trial of its COVID-19 vaccine in adolescents aged 12 to 15 showed 100% efficacy and robust antibody responses, an even better result than seen in an earlier study of participants 16 to 25 years old. The trial involved 2,260 adolescents in the U.S. "We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year," Pfizer Chief Executive Albert Bourla said in a statement.

Pfizer and BioNTech say COVID-19 vaccine was 100% effective in Phase 3 trial in adolescents

The company said it plans to request emergency authorization in the U.S. and Europe “as soon as possible.”

Pfizer Says Its Covid-19 Vaccine Is 100% Effective In Young Teens

The Pfizer-BioNTech COVID-19 vaccine is safe and 100% effective in children as young as 12, its manufacturers have said.

Pfizer vaccine 'safe and 100% effective' in children as young as 12

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have reported Phase 3 trial data evaluating its COVID-19 vaccine BNT162b2 in 2,260 adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection. Efficacy Data: Data demonstrated 100% efficacy and substantial antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated.

Pfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents

Pfizer-BioNTech's COVID-19 vaccine was 100% effective at preventing COVID-19 infection in kids aged 12 to 15, the company announced Wednesday. "In participants aged 12-15 years old, [Pfizer's COVID-19 vaccine] demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis and it was well tolerated," Pfizer said in a press release.

Pfizer's COVID-19 vaccine is 100% effective in 12 to 15 year olds, paving the way for approval for kids in the US and Europe

Pfizer Inc. and German partner BioNTech SE said Wednesday a Phase 3 trial of its COVID-19 vaccine in adolescents aged 12 to 15 years old showed 100% efficacy and robust antibody responses, an even better result that seen in an earlier study of participants aged 16 to 25 years old. The trial involved 2,260 adolescents in the U.S..

Pfizer and BioNTech say trial of COVID vaccine was 100% effective in Phase 3 trial of adolescents

Pfizer plans to submit the new vaccine data to the FDA "as soon as possible," CEO Albert Bourla said.

Pfizer says Covid vaccine is 100% effective in kids ages 12 to 15

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. These are topline results from a pivotal Phase 3 tria

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

BioNTech SE (BNTX) CEO Ugur Sahin on Q4 2020 Results - Earnings Call Transcript

The German biotech delivered huge revenue growth and posted a hefty profit thanks to its COVID-19 vaccine.

BioNTech's Q4 Results Wowed but Were Just the Tip of the Iceberg

BioNTech stock jumped Tuesday after the company projected $11.5 billion in Covid vaccine sales based on its existing contracts. The company expects to make 2.5 billion doses in 2021.

BioNTech Stock Pops As Company Projects $11.5 Billion In Covid Vaccine Sales

BioNTech SE (NASDAQ: BNTX) reported Q4 sales of €345.4 million compared to €28 million a year ago, primarily attributable to recognizing revenues for the first time under two new collaboration agreements to develop a COVID-19 vaccine and ultimately led to the recognition of COVID-19 vaccine commercial revenues. Earnings: Commercial revenues comprise around €188.5 million of gross profit from COVID-19 vaccine sales in the collaboration partner's territory, representing a net figure.

BioNTech Stock Is Trading Higher On First Annual Profit; Raises 2021 Production Target For COVID-19 Shots To 2.5B Doses

Shares of BioNTech (NASDAQ:BNTX) rose 5.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 767.86% year over year to $1.87, which beat the estimate of ($0.18).

BioNTech: Q4 Earnings Insights

The biotech and Pfizer have orders for 1.4 billion doses to be delivered in 2021.

BioNTech Expects $11.5 Billion in Covid-19 Vaccine Revenue

Conference call and webcast scheduled for March 30, 2021, at 08:00 a.m. ET (2:00 p.m. CET)

BioNTech Announces Full Year 2020 Financial Results and Corporate Update

Chewy

CarMax

Lululemon Athletica

Micron Technology

Walgreens

Earnings reports from Chewy, Lululemon, McCormick, Micron, Walgreens, and CarMax. Plus, jobs Friday, manufacturing PMIs, and consumer confidence data.

Chewy, Walgreens, Lululemon, Micron, BioNTech and Other Stocks to Watch This Week

The city stopped using the vaccine after it found defective vials, but it now says there's “no evidence indicating any safety risks.”

Probe Finds No Safety Problems With BioNTech Vaccine Packaging After Hong Kong Halts Shots

Canoo

Next week's earnings reports get off to a slow start, with just one report of interest coming Monday after markets close and one more before markets open Tuesday morning.

Earnings Previews: Canoo, BioNTech

BioNTech SE said Friday that the European Medicines Agency (EMA) has approved its Marburg facility in Germany for the manufacture of the COVID-19 vaccine drug substance, which would boost annual vaccine production capacity by one billion does a year when full operational. BioNTech, which along with U.S.-based partner Pfizer Inc. makes the COVID-19 vaccine, said it can now deliver the drug product batches of the vaccine to partner sites, for sterile fill and finish, and expects the first batches of the vaccines made at the Marburg site to be delivered in the second half of April.

BioNTech's Marburg facility gets EMA approval, boosting COVID-19 vaccine production capacity by a billion doses a year

MAINZ, GERMANY, March 26, 2021 (GLOBE NEWSWIRE) — BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA, at the Marburg site over the course of this week. The approvals make BioNTech's Marburg manufacturing site one of the largest mRNA vaccine manufacturing sites in Europe as well as worldwide with an annual production capacity of up to one billion doses of our COVID-19 vaccine, once fully operational. Due to optimized operational efficiencies which were initiated last year, BioNTech has been able to increase the expected annual manufacturing capacity by 250 million doses.

BioNTech provides Update on Vaccine Production Status at Marburg Manufacturing Site

New York and Mainz, Germany, March 26 , 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EMA) approved storage of COMIRNATY® at -25°C to -15°C for a total of two weeks based on data showing the stability at these temperatures in standard pharmaceutical freezers. The new data is a testament to the companies' ongoing commitment to developing this vaccine further and collecting data in order to support broader and more flexible vaccine distribution and inoculation. With this approval, the COMIRNATY vials can be stored in all 27 European Union (EU) member states at these updated temperatures for a total of two weeks alternatively to the storage at ultra-low temperatures. It marks an important milestone in the vaccine roll-out, as it could allow storage in pharmacies to support vaccinations at local practices/doctors' offices. By enabling more individuals to store and administer the vaccine, the approval will help broaden access, while limiting strain on larger vaccination centers.

EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union

The company, which developed its Covid-19 vaccine with Pfizer, partners with Shanghai Fosun Pharmaceutical on the vaccine in greater China.

Hong Kong Halts Use of BioNTech Vaccine Over Packaging Issues

AstraZeneca

Johnson & Johnson

Moderna

Novavax

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

Vaccine maker BioNTech and its Chinese partner Fosun Pharma say they have found no reason to believe the defect may have caused a safety issue.

News for BioNTech SE Stock (BNTX)